Astrazeneca (AZN) said Tuesday its Calquence fixed-duration regimen was recommended by the European Medicines Agency's Committee for Medicinal Products for Human Use to treat adults with previously untreated chronic lymphocytic leukaemia.
CHMP's positive opinion was based on a phase 3 trial that indicated that Calquence combinations with venetoclax and obinutuzumab showed improved progression-free survival compared with chemoimmunotherapy, according to a statement.
Shares were up 0.6% in recent trading.
Price: 70.38, Change: +0.45, Percent Change: +0.64
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.